Compare ELSE & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | QNRX |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 14.5M |
| IPO Year | 1995 | 2023 |
| Metric | ELSE | QNRX |
|---|---|---|
| Price | $4.35 | $8.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 24.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $9,373,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $71.67 | ★ N/A |
| Revenue Growth | ★ 9.56 | N/A |
| 52 Week Low | $3.65 | $0.21 |
| 52 Week High | $5.29 | $41.80 |
| Indicator | ELSE | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 47.01 |
| Support Level | $4.07 | $8.03 |
| Resistance Level | $4.45 | $10.05 |
| Average True Range (ATR) | 0.05 | 0.80 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 56.52 | 47.73 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.